TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03948828
Drug: GnRHa combained with reverse addition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patients were treated with GnRHa combined with reverse addition treatment.
Study: NCT02019329
Drug: RO5545965
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily administration from Days 1-12
Study: NCT00290966
Drug: XRP6976
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03038425
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
Study: NCT01849770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00467454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT00973076
Drug: AZD8055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, orally administered, twice daily
Study: NCT04173429
Drug: Nadroparin calcium, warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study: NCT01031927
Drug: N-methyl glycine
Normalized name: N-methyl-pyrrolidone
DrugBank: Methyl pyrrolidone (DB12521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
Study: NCT00953901
Drug: Fresh Frozen Plasma Transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01154790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects: study drug 2 subjects: placebo
Study: NCT01724658
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally twice a week with progynova 1 mg oral daily
Study: NCT01154790
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 subjects: study drug 2 subjects: placebo
Study: NCT03604965
Drug: GP+CCRT
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
Study: NCT03604965
Drug: TPF+CCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
Study: NCT04577443
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Study: NCT00830258
Drug: Pravastatin sodium 80 mg tablets
Normalized name: pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 80 mg
Study: NCT03595202
Drug: TS-143
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
Study: NCT03595202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
Study: NCT01934036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
Study: NCT00401479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02329288
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04060836
Drug: Recombinant Coagulation Factor VIII Injection
Normalized name: coagulation factor VIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Study: NCT01022580
Drug: Infasurf surfactant (ONY, Inc.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
Study: NCT01022580
Drug: Sham (No Treatment)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
Study: NCT02844114
Drug: Ganoderma lucidum spore
Normalized name: Ganoderma lucidum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: G 300mg, 5 tablets by mouth
Study: NCT02844114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic tramadol 1500mg tablet
Study: NCT02844114
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv.30 minutes
Study: NCT02057835
Drug: Placebo to BI 691751
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BI 691751
Study: NCT00541229
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
Study: NCT02057835
Drug: BI 691751 low dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 691751 low dose 2
Study: NCT02262299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recieve tablets with placebo
Study: NCT02525822
Drug: IDP-123 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product: IDP-123 Lotion
Study: NCT03233854
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03233854
Drug: NKTR-255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02404753
Drug: Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
Study: NCT00783510
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As prescribed by treating physician
Study: NCT04434144
Drug: Ivermectin + Doxycycline
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
Study: NCT02525822
Drug: Tazorac Cream, 0.1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Product: Tazorac Cream, 0.1%
Study: NCT02525822
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Product: Vehicle Cream
Study: NCT03515369
Drug: Babaodan oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
Study: NCT03515369
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
Study: NCT00990288
Drug: Hemostatic Matrix
Normalized name: Floseal Hemostatic Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
Study: NCT03307915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
Study: NCT00404183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets BID
Study: NCT00376493
Drug: metronidazole and doxycycline
Normalized name: metronidazole and diloxanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
Study: NCT00795106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
Study: NCT01095731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
Study: NCT00455312
Drug: Campath 1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
Study: NCT00455312
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
Study: NCT02223897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
Study: NCT01045018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 400 mg
Study: NCT00834418
Drug: ARAVA™ 20 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 20 mg, single-dose fasting
Study: NCT01408641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules without topiramate
Study: NCT04434144
Drug: Hydroxychloroquine + Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
Study: NCT00443651
Drug: Anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
Study: NCT00777023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Study: NCT02010918
Drug: glucosamine sulfate /chondroitin sulfate - capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
Study: NCT02010918
Drug: glucosamine sulfate /chondroitin sulfate - sachet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
Study: NCT02010918
Drug: Cosamin DS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
Study: NCT02380794
Drug: Danshen Gegen Capsule
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption.
Study: NCT02380794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03683667
Drug: Azithromycin Oral Product
Normalized name: azithromycin Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
Study: NCT03683667
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contain inert excipients only
Study: NCT03461757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ODT to match rimegepant dose QD
Study: NCT00270517
Drug: EDP-420 / Duration of Treatment - 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00270517
Drug: Telithromycin / Duration of Treatment - 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04715295
Drug: Doxycycline Tablets
Normalized name: Doxycycline Tablets
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 200 mg daily for 7 days
Study: NCT03835286
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
Study: NCT01830335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00932841
Drug: VSL#3 900 billion bacteria
Approvals — FDA: no, EMA: no, PMDA: no
Description: One packet PO daily, x 8 weeks
Study: NCT00932841
Drug: VSL#3 90 billion bacteria
Approvals — FDA: no, EMA: no, PMDA: no
Description: One packet PO daily, x 8 weeks.
Study: NCT02601963
Drug: FMX-103 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Study: NCT02601963
Drug: FMX-103 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Study: NCT02271503
Drug: CD-LD IR
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
Study: NCT00836472
Drug: Glucovance® 5 mg/500 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 5 mg/500 mg, single-dose fasting
Study: NCT00076674
Drug: Intravenous Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03092466
Drug: femoral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
Study: NCT01706159
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
Study: NCT03092466
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of saline solution (15ml) in femoral catheter
Study: NCT00671320
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
Study: NCT00671320
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
Study: NCT03325387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00723164
Drug: Fentanyl and Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
Study: NCT02190058
Drug: DS-1971a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: suspension
Study: NCT02190058
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching DS-1971a
Study: NCT02605265
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00575159
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug
Study: NCT00575159
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT00003659
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
Study: NCT03517085
Drug: steroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
Study: NCT00921700
Drug: Ibuprofen + Paracetamol
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
Study: NCT00921700
Drug: Ibuprofen + Paracetamol + Codeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
Study: NCT00921700
Drug: Paracetamol + Codeine
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
Study: NCT00921700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of lactose as placebo in gelatine capsules
Study: NCT01791192
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod
Study: NCT01791192
Drug: Oral Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Corticosteroid
Study: NCT00803725
Drug: Mepivacaine without fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg 1.5% mepivacaine injection for spinal anesthesia
Study: NCT00803725
Drug: Mepivacaine with Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
Study: NCT03979274
Drug: Reference Eutirox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
Study: NCT03979274
Drug: Test Eutirox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
Study: NCT00935558
Drug: aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
Study: NCT01665144
Drug: BAF312
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25, 0.5, 1, and 2 mg film-coated tablets
Study: NCT01665144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets
Study: NCT02805101
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodentine is going to be used as the sealing agent for the perforation.
Study: NCT03824665
Drug: Fentanyl Group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline
Study: NCT00137254
Drug: Stable Isotopes
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of stable isotopes
Study: NCT04267276
Drug: Part 1: BI 1265162 - intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution
Study: NCT04267276
Drug: Part 2: BI 1265162 - oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution